Skip to main content
main-content

The independent medical news service

24-11-2022 | Neurology | News | Article

FIREFISH 2-year data show continued benefit of risdiplam for type 1 SMA

The 24-month results from part 2 of the open-label FIREFISH trial suggest that prolonged treatment with risdiplam is associated with continued improvements in motor function and development in infants with type 1 spinal muscular atrophy.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

27-10-2022 | Neurology | News | Article

VALOR hints at potential benefit of tofersen for SOD1 amyotrophic lateral sclerosis

Data from the open-label extension of the VALOR trial suggest that treatment with the intrathecally administered antisense oligonucleotide tofersen may modify the disease course of amyotrophic lateral sclerosis due to SOD1 mutations and lead to improvements in function.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

09-09-2022 | Neurology | News | Article

Monoclonal antibodies disappoint in early Parkinson’s disease

Two monoclonal antibodies targeting aggregated α-synuclein have failed to improve clinical or imaging measures of Parkinson’s disease progression in the early-stage setting.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

07-07-2022 | Neurology | News | Article

Ultrahigh-dose methylcobalamin shows promise for early-stage ALS

Treatment with ultrahigh-dose methylcobalamin may slow the functional decline of amyotrophic lateral sclerosis patients with early-stage disease and a moderate progression rate, indicate Japanese trial data published in JAMA Neurology.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

19-05-2022 | Neurology | News | Article

Night-time apomorphine improves sleep disturbances in people with Parkinson’s disease

A night-time only infusion of the dopamine agonist apomorphine could help to reduce sleep disturbances in patients with advanced Parkinson’s disease and moderate-to-severe insomnia, suggest the results of the APOMORPHEE trial.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

05-05-2022 | Neurology | News | Article

TREM2 may have protective effect in Alzheimer’s disease

Researchers have identified an association between faster rates of increase of TREM2 levels in soluble cerebrospinal fluid and slower progression of several markers of disease evolution in participants of the Dominantly Inherited Alzheimer Network, which they say points to a likely protective effect of TREM2 during the early pathogenesis of Alzheimer’s disease.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

03-05-2022 | Rheumatology | News | Article

Data do not support targeted DMARDs for dementia risk reduction

Treatment with DMARDs that target cytokine signaling is not associated with a reduced risk for Alzheimer’s disease and related dementia in people with rheumatoid arthritis, US researchers report.

07-04-2022 | Neurology | News | Article

Serum NfL could serve as a biomarker in spinocerebellar ataxia type 1

Serum levels of neurofilament light protein are elevated in both the pre-ataxic and ataxic stages of spinocerebellar ataxia type 1, and are associated with onset of ataxia, shows research published in Neurology.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

03-03-2022 | Neurology | News | Article

BDNF Val66Met modifies outcomes in dominantly inherited Alzheimer’s disease

The Val66Met polymorphism of the brain-derived neurotrophic factor gene may be “an important moderator” of clinical and tau outcomes in people with dominantly inherited Alzheimer’s disease, say researchers.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

10-02-2022 | Neurology | News | Article

SUNFISH shows efficacy of risdiplam in patients with spinal muscular atrophy

Risdiplam significantly improves the motor function of patients aged 2–25 years with type 2 or nonambulant type 3 spinal muscular atrophy relative to placebo, report the SUNFISH investigators in The Lancet Neurology.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

01-02-2022 | Rheumatology | News | Article

DMARD use does not impact Parkinson’s disease risk in RA

Overall use of DMARDs or corticosteroids is not associated with a reduced risk for Parkinson’s disease in people with rheumatoid arthritis, but chloroquine or hydroxychloroquine use may be, show results of a nationwide case-control study.

20-01-2022 | Neurology | News | Article

Plasma p-tau levels linked to cognitive decline in people with Lewy body dementia

Plasma levels of phosphorylated-tau proteins could serve as a biomarker for cognitive decline in individuals with dementia with Lewy bodies, say researchers who found an association between increasing levels of the proteins and more rapid decline in Mini-Mental State Examination scores over time.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

11-11-2021 | Neurology | News | Article

Plasma GFAP ‘a sensitive biomarker’ for early amyloid-β pathology

Plasma glial fibrillary acidic protein outperforms its cerebrospinal fluid counterpart in the detection of amyloid-β pathology even in the early stages of Alzheimer’s disease, indicates a cross-sectional study.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

18-10-2021 | Neurology | News | Article

Methylphenidate offers apathy treatment hope for Alzheimer’s disease patients

Methylphenidate is effective for the treatment of apathy in patients with Alzheimer’s disease, suggest study findings published in JAMA Neurology.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

19-05-2020 | Oncology | News | Article

TAILORx sheds light on cognitive decline in early-stage breast cancer

An analysis of the TAILORx trial has revealed early, but not sustained, cognitive decline among breast cancer patients treated with adjuvant chemoendocrine therapy relative to endocrine therapy alone.

01-04-2020 | Oncology | News | Article

Breast cancer treatments may ward off Alzheimer’s disease

Research suggests that women who use hormone-modulating breast cancer treatments such as tamoxifen or aromatase inhibitors may experience a reduced risk for neurodegenerative disease.

25-11-2019 | Diabetes | News | Article

CGM may be feasible in older people with memory problems

Findings from a UK feasibility study suggest that continuous glucose monitoring is an acceptable approach for older people with diabetes and memory problems, but devices with automated transfer of glucose readings may be needed to improve completeness of data capture.

02-05-2019 | Rheumatology | News | Article

Multifactorial nature of cognitive dysfunction highlighted in SLE

Poor attenuation of the default mode network regions of the brain may contribute to cognitive impairments in patients with systemic lupus erythematosus, say UK researchers.

07-02-2019 | Alzheimer's disease | News | Article

Early tau deposition findings support sex differences in AD risk

Researchers have found that clinically healthy women with high amyloid burden have elevated tau deposition compared with men.

31-01-2019 | Parkinson's disease | News | Article

Early levodopa treatment not justified in Parkinson’s disease

Levodopa does not modify Parkinson’s disease, show study findings suggesting there is no benefit to starting the drug early in the disease course.